📰 Telangana Next-Gen Life Sciences Policy 2026-30: Cabinet Accord

The Telangana State Cabinet, chaired by Chief Minister A. Revanth Reddy, officially approved the 'Next Generation Life Sciences Policy 2026-30' on May 23, 2026. The primary objective of this policy is to position Telangana among the top 5 global life sciences clusters by 2030. Over the next five years, the policy aims to attract $25 billion (approximately ₹2 lakh crore) in investments and generate 500,000 new employment opportunities. Shifting the state's traditional focus from bulk drug manufacturing to high-value innovation, this framework introduces structural reforms to boost cutting-edge biological research.

What Happened

The Telangana State Cabinet, led by Chief Minister A. Revanth Reddy, passed the 'Next Generation Life Sciences Policy 2026-30' during its administrative briefing on May 23, 2026. The state government had previously introduced the foundational framework of this policy to global investors at the World Economic Forum (WEF) annual meeting in Davos, Switzerland, in January 2026. Following formal cabinet ratification, the comprehensive policy will now be operationalized across the state. The policy transitions Telangana from a low-cost generic manufacturing hub into an ecosystem focused on high-value biopharmaceutical innovations and proprietary drug development.

When & Where

The cabinet approval was finalized at the State Secretariat in Hyderabad on May 23, 2026. Structurally, the policy targets core industrial zones surrounding Hyderabad, including Genome Valley, the Medical Devices Park, and the newly planned Green Pharma City. This multi-year framework arrives at a time when global healthcare sectors are integrating artificial intelligence (AI) and digital health into biological manufacturing systems.

Who Is Involved

The implementation of the five-year policy involves several high-level public and private stakeholders:

A. Revanth Reddy: Chief Minister of Telangana, who originally announced the state's global life sciences vision at Davos.
Duddilla Sridhar Babu: Minister for IT, Electronics, and Industries, serving as the nodal political authority supervising the roll-out.
Department of Industries & Commerce: The administrative state department managing land allocation, infrastructure setups, and ease-of-doing-business clearances.
Global Biopharma Corporations: Multinationals such as Sanofi, Amgen, Eli Lilly, and Bristol Myers Squibb, which are expanding their research presence in Hyderabad.

How It Works

The Next-Gen Life Sciences Policy operates through four distinct strategic pillars:

Industrial Recognition for R&D: In a significant structural reform, standalone Research and Development (R&D) units will be recognized as full industrial enterprises. This grants them access to industrial power tariffs, land subsidies, and state incentives previously reserved for physical factories.
Focus on Frontier Technologies: Directing capital investments toward next-generation medical sciences, including Cell and Gene Therapy (CGT), mRNA platforms, CRISPR gene editing, and Antibody-Drug Conjugates (ADCs).
Cluster-Based Infrastructure: Establishing ten advanced 'Pharma Villages' along the Hyderabad Outer Ring Road (ORR) equipped with Zero Liquid Discharge (ZLD) treatment facilities to ensure sustainable operations.
Public-Private Venture Funding: Launching a dedicated 'Life Sciences Innovation Fund' with an initial government corpus that will scale up to ₹1,000 crore through private venture capital match-funding to seed early-stage biotech startups.

Why It Matters

This policy holds immense economic and scientific significance for competitive examinations, linking directly to TSPSC Group 1 and UPSC GS Paper 3 (Economic Development, Science and Technology). Economically, attracting ₹2 lakh crore in capital investments will expand the state’s gross domestic product and secure formal employment for half a million science graduates. Scientifically, by indigenizing advanced bio-manufacturing capabilities, the policy mitigates India's over-dependence on foreign imports for Active Pharmaceutical Ingredients (APIs), boosting national health security.

Historical Background

Over the past three decades, Hyderabad has established itself as the healthcare manufacturing backbone of India. The journey began in the late 1990s with the launch of Genome Valley, which became India's first systematically planned organized biotechnology cluster. This was followed by the creation of the Medical Devices Park, the largest specialized medical equipment cluster in the country. Having attracted over ₹73,000 crore in life sciences investments during the last two years alone, the state designed this 'Next-Gen' 2026-30 policy to build upon this industrial heritage.

Previous Related Events

The passage of this policy follows international developments, such as the Quad alliance's July 2025 initiative to secure global biotechnology and critical mineral supply chains. Furthermore, during the Davos summit in January 2026, the Telangana state delegation finalized initial Memorandums of Understanding (MoUs) worth nearly ₹30,000 crore with international healthcare firms, which provided the immediate momentum for this policy's cabinet approval.

Static GK Connection

The administrative and technical concepts of this policy tie into standard constitutional and scientific principles:

Seventh Schedule of the Indian Constitution: 'Industries' fall under Entry 24 of the State List (List II), granting state governments the legislative autonomy to draft independent industrial guidelines.
Intellectual Property Rights (IPR): Value-led pharmaceutical growth relies heavily on patent frameworks governed by the Indian Patents Act, 1970 and international TRIPS standards.

India & World Comparison

Globally, regions like Boston (USA) and Basel (Switzerland) lead the world in high-value life science innovations. Within India, states like Maharashtra, Gujarat, and Karnataka compete for pharmaceutical investments. However, Telangana maintains an advantage by hosting the highest number of USFDA-approved manufacturing facilities globally and single-handedly supplying 33 percent of the world's total vaccine requirements.

Future Impact

By the conclusion of the policy period in 2030, Telangana's life sciences ecosystem is projected to reach an economic valuation of $250 billion. To meet the expected demand for specialized talent, the government plans to establish the 'Telangana School of Life Sciences' as a premier research university. Additionally, the integration of Artificial Intelligence inside newly planned Global Capability Centers (GCCs) in Hyderabad will accelerate automated drug discovery and clinical trials.

🔑 Key Points for Revision

The Telangana Cabinet approved the Next-Gen Life Sciences Policy 2026-30 on May 23, 2026.
The state targets positioning its life sciences sector among the top 5 global clusters by 2030.
The policy aims to attract $25 billion (₹2 lakh crore) in investments over a five-year period.
It targets the creation of 500,000 new employment opportunities across high-tech scientific sectors.
Standalone R&D units will receive full legal classification as industrial enterprises for state subsidies.
A ₹1,000 crore Life Sciences Innovation Fund will provide venture capital to startup entities.
Ten specialized Pharma Villages will be constructed along the Outer Ring Road infrastructure corridor.
Industrial zones under this framework will mandate Zero Liquid Discharge (ZLD) to protect ecosystems.
The policy seeks to expand pharmaceutical services from $2 billion to $10 billion by 2030.
The specialized 'Telangana School of Life Sciences' university will be established to develop human capital.
Telangana accounts for 40 percent of India's total domestic pharmaceutical production output.
Hyderabad produces one-third of the global vaccine supply, serving as a global healthcare capital.
Focused sub-sectors include CRISPR gene editing, mRNA platforms, and Cell and Gene Therapy (CGT).
The framework promotes the setup of AI-driven Global Capability Centers (GCCs) for drug discovery.
Industries are governed via Entry 24 of the State List under the Seventh Schedule of the Constitution.

🧠 Concept Link (Static GK Deep Dive)

Core Concept: Value-Led Innovation vs. Volume-Led Manufacturing

Definition: 'Volume-led manufacturing' refers to the low-cost mass production of standard generic medicines. 'Value-led innovation' focuses on high-investment research to discover new patentable molecules, therapies, and specialized medical solutions.
Constitutional / Legal Basis: Grounded in Entry 24 (Industries) of the State List and Entry 20 (Economic and Social Planning) of the Concurrent List within the Seventh Schedule.
Scientific / Economic Principle: Built on the economic principle of the 'Knowledge Economy,' where intellectual capital and research generate higher profit margins and insulate a nation from commodity market fluctuations.
How it connects to this event: The Telangana Next-Gen Policy 2026-30 acts as an administrative mechanism designed to elevate the state's pharmaceutical sector from basic generic manufacturing (volume) to advanced molecular innovation (value).
Origin & History: India's generic sector grew rapidly following the Patents Act of 1970, which allowed process patenting. The system shifted in 2005 when India amended its laws to comply with WTO TRIPS standards, reintroducing product patents.
Key milestone 1: The launch of Genome Valley in 1999 outside Hyderabad established India's first dedicated, organized biotech cluster.
Key milestone 2: The notification of the National IPR Policy in 2016 streamlined patent application procedures to incentivize domestic inventors.
Related Acts / Schemes / Treaties: Central initiatives like the Production Linked Incentive (PLI) Scheme for Pharmaceuticals and the Drugs and Cosmetics Act, 1940.
Nodal Ministry / Body: Domestically regulated by the Department of Pharmaceuticals under the Union Ministry of Chemicals and Fertilizers; executed regionally by the State Department of Industries.
India-specific relevance: While India is known as the 'Pharmacy of the World,' developing value-led innovation reduces reliance on external nations (like China) for key raw inputs and APIs.
Global comparison: While China dominates low-cost bulk raw chemical production, the United States and Switzerland lead global healthcare earnings through value-led patent innovations.
Data point: India's standing in the Global Innovation Index (GII) has shown consistent improvement due to targeted regional R&D policies.
Common exam angle: Questions frequently analyze biotech applications (gene editing, stem cells), regional industrial clusters, and the structural challenges of transitioning from generics to drug discovery.
Easy memory hook: From Volume to Value — the core philosophy driving the 2026-30 industrial strategy.

❓ Practice MCQs

Q1. What is the official operative timeline of the Next-Gen Life Sciences Policy approved by the Telangana Cabinet in May 2026?

A) 2025-2030

B) 2026-2030

C) 2026-2031

D) 2025-2035

Answer: B

Explanation: The Telangana State Cabinet officially approved the policy to run for a five-year period spanning from 2026 to 2030.

Q2. What total investment target does the Telangana Next-Gen Life Sciences Policy 2026-30 aim to attract over its operative duration?

A) $10 billion

B) $15 billion

C) $25 billion

D) $50 billion

Answer: C

Explanation: The policy targets attracting a total of $25 billion (approximately ₹2 lakh crore) in capital investments into the state's life sciences ecosystem.

Q3. Under the newly approved 2026-30 policy, which entities will be legally recognized as full 'industrial enterprises' to receive state manufacturing subsidies?

A) Pharmaceutical transport networks

B) Standalone Research and Development (R&D) units

C) Local retail pharmacy stores

D) Herbal packaging centers

Answer: B

Explanation: To foster innovation, standalone R&D units will now be legally classified as industrial enterprises, granting them identical operational subsidies.

Q4. Where did the Telangana state government initially unveil the foundational draft of this Life Sciences Policy to international investors in January 2026?

A) United Nations General Assembly, New York

B) World Economic Forum, Davos

C) BRICS Summit, Moscow

D) Global Bio-India Summit, New Delhi

Answer: B

Explanation: Chief Minister A. Revanth Reddy originally presented the investment roadmap at the World Economic Forum (WEF) annual session in Davos, Switzerland, in January 2026.

Q5. What is the maximum scalable target value of the Life Sciences Innovation Fund established under the new policy framework?

A) ₹100 crore

B) ₹500 crore

C) ₹1,000 crore

D) ₹2,000 crore

Answer: C

Explanation: The innovation fund starts with public backing and is designed to leverage private co-investments to scale up to a total pool of ₹1,000 crore.

Q6. How many specialized 'Pharma Villages' does the policy propose to build along the Outer Ring Road (ORR) infrastructure corridor?

A) 5 Pharma Villages

B) 10 Pharma Villages

C) 15 Pharma Villages

D) 20 Pharma Villages

Answer: B

Explanation: The infrastructure master plan designates the creation of ten (10) specialized Pharma Villages along the Outer Ring Road corridor.

Q7. Telangana single-handedly contributes approximately what percentage share to India's total domestic pharmaceutical production output?

A) 20 percent

B) 30 percent

C) 40 percent

D) 50 percent

Answer: C

Explanation: Telangana serves as a major domestic hub, accounting for roughly 40 percent of India's aggregate pharmaceutical manufacturing volume.

Q8. What is the name of the international-standard academic institution planned under the policy to address specialized human capital requirements?

A) Telangana Biotechnology Academy

B) Hyderabad Institute of Pharma Engineering

C) Telangana School of Life Sciences

D) Genome Research University

Answer: C

Explanation: The state government will establish the 'Telangana School of Life Sciences' to act as a specialized university creating an industry-ready workforce.

📜 Previous Year Question Style (PYQ)

PYQ 1:

Which Indian city is globally recognized as the 'Vaccine Capital of the World' due to its production of one-third of global immunizations and its high concentration of USFDA-approved facilities?

A) Bengaluru

B) Mumbai

C) Ahmedabad

D) Hyderabad

Answer: D

Explanation: Hyderabad hosts clusters like Genome Valley and produces a significant portion of global vaccines, establishing its position as a global biotech center.

PYQ 2:

Consider the following statements regarding the industrial and scientific landscape of Telangana:

Genome Valley, located near Hyderabad, is recognized as India's first organized, systematically planned biotech cluster.
The Next-Gen Life Sciences Policy 2026-30 aims to position Telangana within the top 5 global life sciences clusters by 2030.
The new environmental guidelines for the state's pharmaceutical clusters mandate Zero Liquid Discharge (ZLD) systems.

Which of the statements given above are correct?

A) 1 and 2 only

B) 2 and 3 only

C) 1 and 3 only

D) All of the above

Answer: D

Explanation: All three statements accurately describe the state's historical biotech infrastructure and the newly approved 2026-30 cabinet targets.

PYQ 3:

Under the provisions of the Seventh Schedule of the Constitution of India, the subject matter of 'Industries' falls under which legislative list?

A) Union List (List I)

B) State List (List II)

C) Concurrent List (List III)

D) Residuary Powers

Answer: B

Explanation: 'Industries' are placed under Entry 24 of the State List, giving state assemblies the primary authority to draft regional industrial development policies.

✍️ Mains Answer Pointers

Question 1 (150 words): Outline the key infrastructure-related reforms introduced in the Telangana Next-Gen Life Sciences Policy 2026-30.

Introduction: Identify the policy passed by the Telangana Cabinet on May 23, 2026, which outlines a framework to attract $25 billion in investments via targeted structural upgrades.
Body Point 1: Pharma Villages: The creation of 10 specialized Pharma Villages along the Outer Ring Road (ORR) corridor to decentralize economic growth.
Body Point 2: Environmental Standards: Mandating Zero Liquid Discharge (ZLD) mechanisms across manufacturing zones to ensure eco-friendly biomanufacturing.
Body Point 3: R&D Infrastructure: Extending full industrial status to standalone R&D centers, giving them access to optimized utility tariffs and land allotments.
Conclusion: These infrastructure components are designed to transition the state into a sustainable, globally competitive life sciences ecosystem by 2030.
Data/Diagram to include: A small block diagram mapping the cluster components: Genome Valley + Green Pharma City + 10 ORR Pharma Villages = Top 5 Global Hub.

Question 2 (250 words): Analyze how the transition from 'volume-led manufacturing' to 'value-led innovation' can enhance India's pharmaceutical sovereignty, using the Telangana Life Sciences Policy 2026-30 as a case study.

Introduction: Define the strategic shift from bulk generic manufacturing (volume) to intellectual property creation and advanced therapies (value) as envisioned in the state’s 2026-30 policy.
Body Point 1: Reducing Import Dependencies: Moving up the value chain encourages the domestic development of complex APIs and key starting materials, lowering reliance on single-country import lines.
Body Point 2: Adoption of Frontier Tech: Emphasizing research in mRNA platforms, CRISPR gene editing, and cellular therapies prepares the domestic sector for the future of global medicine.
Body Point 3: Economic Resilience: Patent-driven drug discovery generates significantly higher profit margins than basic generics, insulating the local economy from raw material price volatility.
Body Point 4: Attracting Advanced Investments: Fostering an R&D-friendly environment helps attract global engineering centers, global capability centers (GCCs), and international venture capital into local startups.
Body Point 5: Addressing Talent Mismatches: Mitigating the lack of specialized skills by establishing dedicated institutions, such as the proposed Telangana School of Life Sciences.
Conclusion: Replicating this innovation-first model nationally can help transform India from a generic provider into a creator of advanced global medical solutions.
Data/Diagram to include: A pyramid diagram showing the value hierarchy: generic formulation at the base, shifting upward to complex biologicals, with patented molecular discovery at the apex.

⚠️ Examiner Trap

Trap 1: Question papers might state that the Next-Gen Life Sciences Policy was launched directly by the Central Ministry of Chemicals and Fertilizers. Candidates must remember this is an independent state policy approved by the Telangana Cabinet.
Trap 2: A common wrong assumption is that the ₹1,000 crore Innovation Fund is funded entirely by public tax revenues. The reality is that it uses a Public-Private Partnership (PPP) model designed to draw in private venture capital.
Trap 3: Students might overlook the significance of granting industrial status to R&D units, assuming it is a symbolic title change. In exams, emphasize that this change provides a legal basis for units to claim real financial and utility subsidies.

🧭 Exam Tip

Prelims Focus: Memorize the numerical indicators: the target year (2030), the investment goal ($25 billion), the employment target (500,000), and the number of proposed Pharma Villages (10).
Mains Focus: Use this policy as a contemporary case study when answering questions on industrial diversification, public-private partnerships, biotechnology applications, or regional economic planning.
Interview Perspective: If questioned about the environmental pollution traditionally linked to bulk drug units, explain how this policy uses Zero Liquid Discharge (ZLD) and green clusters to balance economic growth with environmental care.
High-Probability Prediction: A question regarding the legal reclassification of R&D units as industrial enterprises or the setup of specialized biotech funds is highly likely to appear in the upcoming state and national exam cycles.

📰 Telangana Next-Gen Life Sciences Policy 2026-30: Cabinet Accord

What Happened

When & Where

Who Is Involved

The implementation of the five-year policy involves several high-level public and private stakeholders:

A. Revanth Reddy: Chief Minister of Telangana, who originally announced the state's global life sciences vision at Davos.
Duddilla Sridhar Babu: Minister for IT, Electronics, and Industries, serving as the nodal political authority supervising the roll-out.
Department of Industries & Commerce: The administrative state department managing land allocation, infrastructure setups, and ease-of-doing-business clearances.
Global Biopharma Corporations: Multinationals such as Sanofi, Amgen, Eli Lilly, and Bristol Myers Squibb, which are expanding their research presence in Hyderabad.

How It Works

The Next-Gen Life Sciences Policy operates through four distinct strategic pillars:

Industrial Recognition for R&D: In a significant structural reform, standalone Research and Development (R&D) units will be recognized as full industrial enterprises. This grants them access to industrial power tariffs, land subsidies, and state incentives previously reserved for physical factories.
Focus on Frontier Technologies: Directing capital investments toward next-generation medical sciences, including Cell and Gene Therapy (CGT), mRNA platforms, CRISPR gene editing, and Antibody-Drug Conjugates (ADCs).
Cluster-Based Infrastructure: Establishing ten advanced 'Pharma Villages' along the Hyderabad Outer Ring Road (ORR) equipped with Zero Liquid Discharge (ZLD) treatment facilities to ensure sustainable operations.
Public-Private Venture Funding: Launching a dedicated 'Life Sciences Innovation Fund' with an initial government corpus that will scale up to ₹1,000 crore through private venture capital match-funding to seed early-stage biotech startups.

Why It Matters

Historical Background

Previous Related Events

Static GK Connection

The administrative and technical concepts of this policy tie into standard constitutional and scientific principles:

Seventh Schedule of the Indian Constitution: 'Industries' fall under Entry 24 of the State List (List II), granting state governments the legislative autonomy to draft independent industrial guidelines.
Intellectual Property Rights (IPR): Value-led pharmaceutical growth relies heavily on patent frameworks governed by the Indian Patents Act, 1970 and international TRIPS standards.

India & World Comparison

Future Impact

🔑 Key Points for Revision

The Telangana Cabinet approved the Next-Gen Life Sciences Policy 2026-30 on May 23, 2026.
The state targets positioning its life sciences sector among the top 5 global clusters by 2030.
The policy aims to attract $25 billion (₹2 lakh crore) in investments over a five-year period.
It targets the creation of 500,000 new employment opportunities across high-tech scientific sectors.
Standalone R&D units will receive full legal classification as industrial enterprises for state subsidies.
A ₹1,000 crore Life Sciences Innovation Fund will provide venture capital to startup entities.
Ten specialized Pharma Villages will be constructed along the Outer Ring Road infrastructure corridor.
Industrial zones under this framework will mandate Zero Liquid Discharge (ZLD) to protect ecosystems.
The policy seeks to expand pharmaceutical services from $2 billion to $10 billion by 2030.
The specialized 'Telangana School of Life Sciences' university will be established to develop human capital.
Telangana accounts for 40 percent of India's total domestic pharmaceutical production output.
Hyderabad produces one-third of the global vaccine supply, serving as a global healthcare capital.
Focused sub-sectors include CRISPR gene editing, mRNA platforms, and Cell and Gene Therapy (CGT).
The framework promotes the setup of AI-driven Global Capability Centers (GCCs) for drug discovery.
Industries are governed via Entry 24 of the State List under the Seventh Schedule of the Constitution.

🧠 Concept Link (Static GK Deep Dive)

Core Concept: Value-Led Innovation vs. Volume-Led Manufacturing

Definition: 'Volume-led manufacturing' refers to the low-cost mass production of standard generic medicines. 'Value-led innovation' focuses on high-investment research to discover new patentable molecules, therapies, and specialized medical solutions.
Constitutional / Legal Basis: Grounded in Entry 24 (Industries) of the State List and Entry 20 (Economic and Social Planning) of the Concurrent List within the Seventh Schedule.
Scientific / Economic Principle: Built on the economic principle of the 'Knowledge Economy,' where intellectual capital and research generate higher profit margins and insulate a nation from commodity market fluctuations.
How it connects to this event: The Telangana Next-Gen Policy 2026-30 acts as an administrative mechanism designed to elevate the state's pharmaceutical sector from basic generic manufacturing (volume) to advanced molecular innovation (value).
Origin & History: India's generic sector grew rapidly following the Patents Act of 1970, which allowed process patenting. The system shifted in 2005 when India amended its laws to comply with WTO TRIPS standards, reintroducing product patents.
Key milestone 1: The launch of Genome Valley in 1999 outside Hyderabad established India's first dedicated, organized biotech cluster.
Key milestone 2: The notification of the National IPR Policy in 2016 streamlined patent application procedures to incentivize domestic inventors.
Related Acts / Schemes / Treaties: Central initiatives like the Production Linked Incentive (PLI) Scheme for Pharmaceuticals and the Drugs and Cosmetics Act, 1940.
Nodal Ministry / Body: Domestically regulated by the Department of Pharmaceuticals under the Union Ministry of Chemicals and Fertilizers; executed regionally by the State Department of Industries.
India-specific relevance: While India is known as the 'Pharmacy of the World,' developing value-led innovation reduces reliance on external nations (like China) for key raw inputs and APIs.
Global comparison: While China dominates low-cost bulk raw chemical production, the United States and Switzerland lead global healthcare earnings through value-led patent innovations.
Data point: India's standing in the Global Innovation Index (GII) has shown consistent improvement due to targeted regional R&D policies.
Common exam angle: Questions frequently analyze biotech applications (gene editing, stem cells), regional industrial clusters, and the structural challenges of transitioning from generics to drug discovery.
Easy memory hook: From Volume to Value — the core philosophy driving the 2026-30 industrial strategy.

❓ Practice MCQs

Q1. What is the official operative timeline of the Next-Gen Life Sciences Policy approved by the Telangana Cabinet in May 2026?

A) 2025-2030

B) 2026-2030

C) 2026-2031

D) 2025-2035

Answer: B

Explanation: The Telangana State Cabinet officially approved the policy to run for a five-year period spanning from 2026 to 2030.

Q2. What total investment target does the Telangana Next-Gen Life Sciences Policy 2026-30 aim to attract over its operative duration?

A) $10 billion

B) $15 billion

C) $25 billion

D) $50 billion

Answer: C

Explanation: The policy targets attracting a total of $25 billion (approximately ₹2 lakh crore) in capital investments into the state's life sciences ecosystem.

Q3. Under the newly approved 2026-30 policy, which entities will be legally recognized as full 'industrial enterprises' to receive state manufacturing subsidies?

A) Pharmaceutical transport networks

B) Standalone Research and Development (R&D) units

C) Local retail pharmacy stores

D) Herbal packaging centers

Answer: B

Explanation: To foster innovation, standalone R&D units will now be legally classified as industrial enterprises, granting them identical operational subsidies.

Q4. Where did the Telangana state government initially unveil the foundational draft of this Life Sciences Policy to international investors in January 2026?

A) United Nations General Assembly, New York

B) World Economic Forum, Davos

C) BRICS Summit, Moscow

D) Global Bio-India Summit, New Delhi

Answer: B

Explanation: Chief Minister A. Revanth Reddy originally presented the investment roadmap at the World Economic Forum (WEF) annual session in Davos, Switzerland, in January 2026.

Q5. What is the maximum scalable target value of the Life Sciences Innovation Fund established under the new policy framework?

A) ₹100 crore

B) ₹500 crore

C) ₹1,000 crore

D) ₹2,000 crore

Answer: C

Explanation: The innovation fund starts with public backing and is designed to leverage private co-investments to scale up to a total pool of ₹1,000 crore.

Q6. How many specialized 'Pharma Villages' does the policy propose to build along the Outer Ring Road (ORR) infrastructure corridor?

A) 5 Pharma Villages

B) 10 Pharma Villages

C) 15 Pharma Villages

D) 20 Pharma Villages

Answer: B

Explanation: The infrastructure master plan designates the creation of ten (10) specialized Pharma Villages along the Outer Ring Road corridor.

Q7. Telangana single-handedly contributes approximately what percentage share to India's total domestic pharmaceutical production output?

A) 20 percent

B) 30 percent

C) 40 percent

D) 50 percent

Answer: C

Explanation: Telangana serves as a major domestic hub, accounting for roughly 40 percent of India's aggregate pharmaceutical manufacturing volume.

Q8. What is the name of the international-standard academic institution planned under the policy to address specialized human capital requirements?

A) Telangana Biotechnology Academy

B) Hyderabad Institute of Pharma Engineering

C) Telangana School of Life Sciences

D) Genome Research University

Answer: C

Explanation: The state government will establish the 'Telangana School of Life Sciences' to act as a specialized university creating an industry-ready workforce.

📜 Previous Year Question Style (PYQ)

PYQ 1:

Which Indian city is globally recognized as the 'Vaccine Capital of the World' due to its production of one-third of global immunizations and its high concentration of USFDA-approved facilities?

A) Bengaluru

B) Mumbai

C) Ahmedabad

D) Hyderabad

Answer: D

Explanation: Hyderabad hosts clusters like Genome Valley and produces a significant portion of global vaccines, establishing its position as a global biotech center.

PYQ 2:

Consider the following statements regarding the industrial and scientific landscape of Telangana:

Genome Valley, located near Hyderabad, is recognized as India's first organized, systematically planned biotech cluster.
The Next-Gen Life Sciences Policy 2026-30 aims to position Telangana within the top 5 global life sciences clusters by 2030.
The new environmental guidelines for the state's pharmaceutical clusters mandate Zero Liquid Discharge (ZLD) systems.

Which of the statements given above are correct?

A) 1 and 2 only

B) 2 and 3 only

C) 1 and 3 only

D) All of the above

Answer: D

Explanation: All three statements accurately describe the state's historical biotech infrastructure and the newly approved 2026-30 cabinet targets.

PYQ 3:

Under the provisions of the Seventh Schedule of the Constitution of India, the subject matter of 'Industries' falls under which legislative list?

A) Union List (List I)

B) State List (List II)

C) Concurrent List (List III)

D) Residuary Powers

Answer: B

Explanation: 'Industries' are placed under Entry 24 of the State List, giving state assemblies the primary authority to draft regional industrial development policies.

✍️ Mains Answer Pointers

Question 1 (150 words): Outline the key infrastructure-related reforms introduced in the Telangana Next-Gen Life Sciences Policy 2026-30.

Introduction: Identify the policy passed by the Telangana Cabinet on May 23, 2026, which outlines a framework to attract $25 billion in investments via targeted structural upgrades.
Body Point 1: Pharma Villages: The creation of 10 specialized Pharma Villages along the Outer Ring Road (ORR) corridor to decentralize economic growth.
Body Point 2: Environmental Standards: Mandating Zero Liquid Discharge (ZLD) mechanisms across manufacturing zones to ensure eco-friendly biomanufacturing.
Body Point 3: R&D Infrastructure: Extending full industrial status to standalone R&D centers, giving them access to optimized utility tariffs and land allotments.
Conclusion: These infrastructure components are designed to transition the state into a sustainable, globally competitive life sciences ecosystem by 2030.
Data/Diagram to include: A small block diagram mapping the cluster components: Genome Valley + Green Pharma City + 10 ORR Pharma Villages = Top 5 Global Hub.

Introduction: Define the strategic shift from bulk generic manufacturing (volume) to intellectual property creation and advanced therapies (value) as envisioned in the state’s 2026-30 policy.
Body Point 1: Reducing Import Dependencies: Moving up the value chain encourages the domestic development of complex APIs and key starting materials, lowering reliance on single-country import lines.
Body Point 2: Adoption of Frontier Tech: Emphasizing research in mRNA platforms, CRISPR gene editing, and cellular therapies prepares the domestic sector for the future of global medicine.
Body Point 3: Economic Resilience: Patent-driven drug discovery generates significantly higher profit margins than basic generics, insulating the local economy from raw material price volatility.
Body Point 4: Attracting Advanced Investments: Fostering an R&D-friendly environment helps attract global engineering centers, global capability centers (GCCs), and international venture capital into local startups.
Body Point 5: Addressing Talent Mismatches: Mitigating the lack of specialized skills by establishing dedicated institutions, such as the proposed Telangana School of Life Sciences.
Conclusion: Replicating this innovation-first model nationally can help transform India from a generic provider into a creator of advanced global medical solutions.
Data/Diagram to include: A pyramid diagram showing the value hierarchy: generic formulation at the base, shifting upward to complex biologicals, with patented molecular discovery at the apex.

⚠️ Examiner Trap

Trap 1: Question papers might state that the Next-Gen Life Sciences Policy was launched directly by the Central Ministry of Chemicals and Fertilizers. Candidates must remember this is an independent state policy approved by the Telangana Cabinet.
Trap 2: A common wrong assumption is that the ₹1,000 crore Innovation Fund is funded entirely by public tax revenues. The reality is that it uses a Public-Private Partnership (PPP) model designed to draw in private venture capital.
Trap 3: Students might overlook the significance of granting industrial status to R&D units, assuming it is a symbolic title change. In exams, emphasize that this change provides a legal basis for units to claim real financial and utility subsidies.

🧭 Exam Tip

Prelims Focus: Memorize the numerical indicators: the target year (2030), the investment goal ($25 billion), the employment target (500,000), and the number of proposed Pharma Villages (10).
Mains Focus: Use this policy as a contemporary case study when answering questions on industrial diversification, public-private partnerships, biotechnology applications, or regional economic planning.
Interview Perspective: If questioned about the environmental pollution traditionally linked to bulk drug units, explain how this policy uses Zero Liquid Discharge (ZLD) and green clusters to balance economic growth with environmental care.
High-Probability Prediction: A question regarding the legal reclassification of R&D units as industrial enterprises or the setup of specialized biotech funds is highly likely to appear in the upcoming state and national exam cycles.